49 cancer care facilities receive outstanding achievement award from American College of Surgeons Commission on Cancer

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”

FDA has initiated the approval of leucovorin calcium tablets, rushing them to market as part of a push from the Trump administration to identify potential treatments for autism spectrum disorder.

September 26, 2025

Vol.51 No.35

By Claire Marie Porter and Paul Goldberg

Guest Editorial

Population-based cancer surveillance is a national treasure at risk

There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.

September 26, 2025

Vol.51 No.35

By Eric B. Durbin, Karen L. Knight, Betsy Kohler and Sarah Nash

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Chaired by the University of Miami Sylvester Comprehensive Cancer Center, the 24th Cancer Centers Informatics Society (Ci4CC) Symposium will convene the nation’s leading designated and community cancer centers with a central focus on advancing precision oncology.

September 26, 2025

Vol.51 No.35

By Stephen D. Nimer

Trials & Tribulations

Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology

We are rapidly approaching the Sept. 30 planned expiration of telemedicine coverage under Medicaid. Letting this authorization expire is short-sighted. As an oncologist, I believe there are multiple compelling, non-pandemic reasons for telemedicine to remain a permanent fixture in cancer care.

Championing nurse wellbeing as a strategic priority

Working in a comprehensive cancer center requires emotional endurance, strong clinical judgment, and constant interprofessional collaboration, all of which rest on a foundation of personal wellness. For nurses, whose roles are inherently intensive, focusing on wellbeing is integral to their ability to provide safe, compassionate, and effective patient care.

September 26, 2025

Vol.51 No.35

By Kim Slusser

In the Archives

Michael Link reflects on his ASCO presidential term, concerns for the future of oncology—and hope for children with cancer

Appearing on the Cancer History Project Podcast, Michael P. Link, the Lydia J. Lee Professor in Pediatric Oncology at Stanford University, discussed his career in pediatric oncology, his 2011-2012 ASCO presidential term, and voiced concerns about what he’s seeing in oncology today.

September 26, 2025

Vol.51 No.35

49 cancer care facilities receive outstanding achievement award from American College of Surgeons Commission on Cancer

YOU MAY BE INTERESTED IN

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”

Population-based cancer surveillance is a national treasure at risk

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology

Championing nurse wellbeing as a strategic priority

Michael Link reflects on his ASCO presidential term, concerns for the future of oncology—and hope for children with cancer

Renew today!

Subscriber content

Never miss an issue!

Login

49 cancer care facilities receive outstanding achievement award from American College of Surgeons Commission on Cancer

YOU MAY BE INTERESTED IN

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autismExperts call the move “extremely premature”

Population-based cancer surveillance is a national treasure at risk

Ci4CC’s 24th Symposium & Workshop set to focus on precision oncology powered by data intelligence

Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology

Championing nurse wellbeing as a strategic priority

Michael Link reflects on his ASCO presidential term, concerns for the future of oncology—and hope for children with cancer

Never miss an issue!

Login

Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature”